UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

REINDUCTION AND INTENSIFICATION STRATEGY WITH USTEKINUMAB IN IBD PATIENTS, A SINGLE CENTER REAL LIFE EXPERIENCE

Berta López Sáez 1, Luigi Melcarne 1,2, Anna Soria Cadena 3, Eduard Brunet Mas 1,2,4, ANNA PUY GUILLÉN 1, Xavier Calvet Calvo 1,2,4, Laura Patricia Llovet Soto 1, Leticia Hernandez 1, Pilar García Iglesias 1,4, Jordi Vives Moreno 1, Ariadna Altadill 1, Alberto Villoria Ferrer 1,2

Affiliations

1 Corporació Sanitària Parc Taulí, Sabadell, Spain

2 Universidad Autónoma de Barcelona, Bellaterra, Spain

3 Hospital Clínic, Barcelona, Spain

4 CIBERehd. Instituto de Salud Carlos III, Madrid, Spain

Summary

AI Generated

A retrospective cohort study of 32 IBD patients found that dose optimisation with ustekinumab achieved clinical remission in 72% of cases, with secondary failure and extraintestinal manifestations associated with better response.

Among 94 patients on ustekinumab, 32 (30%) required dose optimisation during follow-up, equally divided between primary non-response during induction (50%) and secondary failure (50%).
Clinical remission was achieved in 23 patients (72%) after dose optimisation through reinduction and/or intensification strategies (90mg subcutaneous every 4 or 6 weeks, or 130mg intravenous every 4 weeks).
Secondary failure to ustekinumab (p=0.049) and presence of extraintestinal manifestations (p=0.03) were significantly associated with better response to dose optimisation.
No significant differences in response were observed between different intensification regimens or between patients who received prior reinduction versus those who did not.
The authors conclude that dose optimisation with ustekinumab is useful in clinical practice, particularly for patients with secondary failure; the cohort included predominantly Crohn's disease patients (84.4%) with high rates of prior biologic exposure (87.5%).

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Biological therapy in IBD patients is one of the cornerstones of treatment. For patients with loss of response while on maintenance therapy, options for dose escalation with the same agent are used to avoid switching targets, and this is done through a reinduction and dose intensification. While dose escalation is standard treatment with anti-TNF agents, current data on the efficacy of dose optimisation with ustekinumab in real life is limited.

Aims & Methods

The aim of the study is to assess the efficacy of dose optimisation (reinduction and intensification) therapy with Ustekinumab and to identify prognostic factors associated with clinical response. We performed a retrospective cohort study of patients that received dose optimisation with ustekinumab between January 2016 to July 2022. Demographic and clinical characteristics were obtained from the medical records. To assess for prognostic factors, responders and non-responders were compared using logistic regression analysis.

Results

A total of 94 patients were on ustekinumab treatment, and from these, 32 (30%) patients required dose optimisation during follow-up. The characteristics of patients included are summarized in Table 1. In 16 (50%) patients dose optimization was performed due to lack of response during the induction with Ustekinumab, the other 16 patients (50%) were intensified due to secondary failure. There were 15 (46.9%) patients in whom intravenous reinduction was performed prior to intensification. Three types of intensification were performed: 90mg subcutaneous every 4 weeks, 90mg subcutaneous every 6 weeks or 130mg intravenous every 4 weeks.
In 23 (72%) patients clinical remission was obtained after dose optimisation and were considered responders for logistic regression analysis. Extraintestinal manifestations (p=0.03) and secondary failure to Ustekinumab (p=0.049) were associated with a better response. No significant differences were observed between the type of intensification, the fact that they received prior reinduction or other demographic characteristics.

	n = 32
Gender (% women)	18 (56,2%)
Smokers (%)	8 (25%)
Disease type (%) Crohn’s disease Ulcerative colitis	27 (84,4%) 5 (15,6%)
Disease extension: Crohn’s disease (L1-L2-L3-L4) Ulcerative colitis (E2-E3) Behaviour in Crohn’s disease (B1-B2-B3)	L1 12(37,5%), L2 3 (9,4%), L3 9 (28,1%), L4 3 (9,4%) E2 1 (3,1%), E3 4 (12,5%) B1 9 (28,1%), B2 7 (21,9%), B3 9 (28,1%), B2+3 2 (6,3%)
Surgery (%) Perianal disease (%) Extraintestinal manifestations (%)	10 (31,3%) 14 (43,8%) 15 (46,9%)
Previous treatments (%) Naive Immunosupressor Biologic	4 (2,5%) 19 (59,4%) 28 (87,5%)
Only intensification Reinduction + intensification	17 (53,1%) 15 (46,9%)
Reason for reinduction + intensification Primary failure Secondary failure	16 (50%) 16 (50%)
Type intensification 90mg sc /4 weeks 90mg sc /6 weeks 130mg iv /4 weeks	17 (53,3%) 5 (15,6%) 10 (31,3%)

Table 1. Demographic data and prognostic factors of the cohort.

Conclusion

Dose optimization with ustekinumab is useful in clinical practice with a good response rate, specially in patients with secondary failure.

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

The role of microbiota in MASLD: Basic science and clinical perspective

Herbert Tilg

INTERNATIONAL DELPHI CONSENSUS ON TRAINING IN DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC ULTRASOUND

Paolo Giorgio Arcidiacono

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

THE METABOLIC PRICE OF CURE: LONG-TERM ANTHROPOMETRIC, GLUCOSE AND LIPID SHIFTS FOLLOWING QUADRUPLE THERAPIES FOR HELICOBACTER PYLORI INFECTION

Pedro Narra Figueiredo

MAPS III guidelines: What’s next?

Mario Dinis-Ribeiro

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

The role of microbiota in MASLD: Basic science and clinical perspective

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

The role of microbiota in MASLD: Basic science and clinical perspective

Debbie Shawcross 1, Herbert Tilg 2

Affiliations

1 Kings College London, NHS Foundation Trust, London, United Kingdom

2 Innsbruck Medical University - Department of Medicine, Innsbruck Medical University; Innsbruck/AT, Innsbruck, Austria

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Session

Disease primer: The role of the microbiome in pancreatitis and MASLD

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

The role of microbiota in MASLD: Basic science and clinical perspective

Herbert Tilg

INTERNATIONAL DELPHI CONSENSUS ON TRAINING IN DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC ULTRASOUND

Paolo Giorgio Arcidiacono

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

THE METABOLIC PRICE OF CURE: LONG-TERM ANTHROPOMETRIC, GLUCOSE AND LIPID SHIFTS FOLLOWING QUADRUPLE THERAPIES FOR HELICOBACTER PYLORI INFECTION

Pedro Narra Figueiredo

MAPS III guidelines: What’s next?

Mario Dinis-Ribeiro

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

INTERNATIONAL DELPHI CONSENSUS ON TRAINING IN DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC ULTRASOUND

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

INTERNATIONAL DELPHI CONSENSUS ON TRAINING IN DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC ULTRASOUND

Matteo Tacelli 1, Livia Archibugi 1, Giuseppe Vanella 1, Piera Zaccari 1, Lorenzo Fuccio 2, Antonio Facciorusso 3, Andrada Seicean 4, Adrian Săftoiu 5, Laurent Palazzo 6, Pietro Fusaroli 7, Sundeep Lakhtakia 8, Amrita Sethi 9, Schalk van der Merwe 10, Serena Stigliano 11, Dario Ligresti 12, Marianna Signoretti 13, Daniel De La Iglesia 14, Marco Spadaccini 15, Enrique Perez-Cuadrado-Robles 16, Gianenrico Rizzatti 17, Cecilia Binda 18, Yessica Dominguez-Novoa 19, Belén Martínez Moreno 20, Paraskevas Gkolfakis 21, Aurelio Mauro 22, Andrea Lisotti 23, Daniele Arese 24, Gemma Rossi 1, Maria Chiara Petrone 1, Paolo Giorgio Arcidiacono 1

Affiliations

1 San Raffaele Scientific Institute IRCCS, Milano, Italy

2 S.Orsola-Malpighi University Hospital, Bologna, Italy

3 University of Salento, Lecce, Italy

4 University of Medicine and Pharmacy Iuliu Hatieganu Cluj-Napoca, Cluj Napoca, Romania

5 University of Medicine and Pharmacy Craiova, Craiova, Romania

6 Clinique du Trocadéro, Paris, France

7 University of Bologna, Imola, Italy

8 Asian Institute of Gastroenterology, Hyderabad, India

9 Northwestern Medicine, Illinois, United States

10 UZ Leuven, Leuven, Belgium

11 Campus Biomedico, Roma, Italy

12 IRCCS - ISMETT, Palermo, Italy

13 Sant'Andrea Hospital, Sapienza University, Rome, Italy

14 Galicia Sur Health Research Institute, Vigo, Spain

15 Humanitas University, Rozzano, Italy

16 Georges-Pompidou European Hospital, Paris, France

17 Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy

18 AUSL Romagna, Forlì, Italy

19 University Hospital of Santiago de Compostela, Santiago De Compostela, Spain

20 Hospital General Universitario Dr. Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL, Alicante, Spain

21 Konstantopouleion General Hospital of Nea Ionia, Athens, Greece

22 San Matteo Hospital Foundation, University of Pavia, Milano, Italy

23 Hospital of Imola, University of Bologna, Bologna, Italy

24 Ospedale San Giovanni Bosco, Torino, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Endoscopic ultrasound (EUS) has evolved from a niche tool to a cornerstone of gastroenterology, with expanding diagnostic and therapeutic roles. However, it remains technically demanding, requiring integrated skills and lacking effective simulation models. Training is still largely patient-based, and no standardized, validated curriculum exists, particularly for therapeutic EUS.

Aims & Methods

To develop an international, competency-based framework for training in diagnostic and therapeutic endoscopic ultrasound (EUS) through a structured Delphi consensus. A Delphi process was conducted according to CREDES recommendations. A steering committee defined key domains: prerequisites for trainees/trainers/centers, diagnostic EUS training, and therapeutic EUS training. A total of 130 international experts were invited, and 106 completed the voting process. Statements were refined through two qualitative rounds and voted using a 5-point Likert scale. Consensus was predefined as >=80% agreement.

Results

All statements achieved consensus in the first voting round (agreement range 80–100%). Key recommendations included: requirement of prior competence in upper GI endoscopy (94.6% agreement); minimum annual center volume of >=300 diagnostic EUS (>=75 EUS-TA) to train one trainee/year (93.6%); and >=50 therapeutic EUS/year for training centers (80%). Competency thresholds for trainees included >=250 supervised EUS (up to 450 without post-training support; 84.5%), >=75 EUS-TA (up to 150; 89%), and a diagnostic accuracy target >=85% (96.4%). Quality indicators (e.g., adverse events, diagnostic yield) should be routinely monitored (99.1%).
Training should integrate cognitive and technical skills, structured reporting (100%), and advanced techniques such as CE-EUS and elastography (85.4%). Therapeutic EUS training should follow a stepwise, complexity-based pathway (92.7%), with competency assessed using outcome-based metrics rather than procedural volume alone (98.2%).

Conclusion

This international Delphi consensus establishes a comprehensive, competency-based framework for EUS training, integrating diagnostic and therapeutic procedures. High agreement across all statements supports the transition from volume-based to outcome-driven training, with the aim of standardizing education and improving clinical outcomes.

Event

UEG Week Barcelona 2026

Topics

Pancreas Radiology & Imaging Hepatobiliary Endoscopy

Submission format

Abstract

Session

Biliary clinical care: New frontiers in biliary endoscopy

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

The role of microbiota in MASLD: Basic science and clinical perspective

Herbert Tilg

INTERNATIONAL DELPHI CONSENSUS ON TRAINING IN DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC ULTRASOUND

Paolo Giorgio Arcidiacono

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

THE METABOLIC PRICE OF CURE: LONG-TERM ANTHROPOMETRIC, GLUCOSE AND LIPID SHIFTS FOLLOWING QUADRUPLE THERAPIES FOR HELICOBACTER PYLORI INFECTION

Pedro Narra Figueiredo

MAPS III guidelines: What’s next?

Mario Dinis-Ribeiro

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Vincent Bos 1, Lisanne Pattynama 1, Annick van Nunen 2, Wouter L. Curvers 3, Yasmijn van Herwaarden 4, Pieter Jan de Jonge 5, Jolanda van Dieren 6, Akin Inderson 7, Daan De Koning 8, Robert Laheij 9, peter oosterwijk 10, K. Soufidi 2, Grard A. P. Nieuwenhuijzen 3, Merlijn Hutteman 4, Johanna van Sandick 6, Kirill Basiliya 7, Nina Beekmans 8, Eric Belgers 2, Wietse J. Eshuis 1, Roos E. Pouw 11

Affiliations

1 Amsterdam UMC, Amsterdam, Netherlands

2 Zuyderland Medical Center, Sittard-Geleen, Netherlands

3 Catharina Hospital, Eindhoven, Netherlands

4 Radboud University Medical Center, Nijmegen, Netherlands

5 Erasmus MC, Rotterdam, Netherlands

6 the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

7 Leiden University Medical Center, Leiden, Netherlands

8 Gelre Hospitals, Apeldoorn, Netherlands

9 Elisabeth-Tweesteden Hospital, Tilburg, Netherlands

10 Hospital Group Twente, Almelo, Netherlands

11 UMC Utrecht, Utrecht, Netherlands

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Transmural defects of the upper gastrointestinal (GI) tract can occur due to anastomotic leakage (AL), iatrogenic perforations, and non-iatrogenic perforations, such as Boerhaave syndrome. Upper-GI defects are associated with high morbidity and mortality. Treatment strategies include conservative therapy, endoscopic stenting, percutaneous drainage, surgery, and endoscopic vacuum therapy (EVT). EVT is a relatively novel technique that involves applying negative pressure therapy within the upper-GI lumen or in the cavity behind the defect, often using a vacuum-sponge or vacuum-stent. With a reported success rate of 80-100%, EVT is promising, however, prospective data are scarce, and strategies are not yet standardized or optimized.

Aims & Methods

In this prospective multicenter registry study in 12 hospitals in the Netherlands, we aimed to report the safety and efficacy of EVT for upper-GI transmural defects, to further optimize treatment strategies. All patients (aged ≥ 18 years) treated with EVT ± additional therapy for transmural upper-GI defects between January 2023 - February 2026 were eligible. EVT was performed according to local protocols. The primary outcome was successful EVT, defined as defect closure by EVT. Secondary outcomes included parameters on diagnosis, EVT treatment, additional interventions, and follow-up.

Results

In total, 221 patients (median age 66 years (IQR 58-73), 145 (66%) male) were included. The majority were treated for anastomotic leakage after surgery for malignancy (142/221; 64%) or benign indications (25/221; 11%), followed by iatrogenic defects (33/221; 15%), Boerhaave syndrome (12/221; 5%), other non-iatrogenic defects 9/221; 4%). Defects were detected after a median of 6 days (IQR 3-10). CT scan or contrast swallow examinations were performed in 207/221 (94%) patients and showed contrast leakage in 48%, fluid collections in 37%, and pneumothorax requiring drainage in 14%. An extraluminal cavity was present during endoscopy in 64/221 (29%) patients, which was endoscopically accessible in 42/64 (66%).
EVT was started a median of 1 days (IQR 0-1) after diagnosis of the defect, with a VacStent in 57% or an EsoSponge in 43% as initial EVT. Eventually, 29% patients underwent treatment with EsoSponge only, 47% with VacStent only, and 23% with a combination of EsoSponge and VacStent. Defects were successfully closed in 77% after a median of 16 days (IQR 8-26) and of 4 EVT-related endoscopies (3-6).
EVT failed because closure was not achieved (15%), due to death during treatment (5%), iatrogenic defect expansion of a post-transesophageal echocardiography defect beyond the limits of EVT, resulting in death in one patient who was unfit for surgical rescue (0.5%), or other reasons (2%). EVT-related adverse events (AGREE classification ≥3) occurred in 7%. Patients in whom EVT failed were significantly older (p=.004), were more often treated for non-AL defects (p=.003), had higher perforation severity scores (p<.001), and had a higher number of collections requiring additional percutaneous drainage (p=.015).

Total N = 221	Age (yrs), median (IQR)	CRP (10⁹/L), median (IQR)	Cavity at endoscopy (yes), n (%)	Defect size (mm), median (IQR)	Sponge treatment only, n (%) / success % / EVT duration (days), median (IQR)	VacStent treatment only, n (%) / success % / EVT duration (days), median (IQR)	Sponge+VacStent treatment, n (%) / success % / EVT duration (days), median (IQR)
AL oncologic surgery (n=142)	67 (60-73)	226 (157-310)	39 (27)	3 (0-15)	51 (36) / 76 / 16 (8-28)	55 (39) / 93 / 14 (8-23)	33 (23) / 61 / 27 (19-50)
AL benign surgery (n=25)	53 (45-62)	188 (100-380)	5 (20)	10 (0-10)	3 (12) / 100 / 13 (N/A)	16 (64) / 100 / 15 (7-21)	6 (24) / 83 / 20 (15-52)
Iatrogenic (n=33)	69 (43-76)	140 (16-215)	12 (36)	10 (9-20)	10 (30) / 60 / 11 (6-21)	15 (46) / 73 / 13 (7-15)	8 (24) / 63 / 30 (12-43)
Boerhaave syndrome (n=12)	63 (56-76)	55 (3-223)	7 (58)	30 (20-40)	-	10 (83) / 60 / 10 (7-27)	2 (17) / 50 / 32 (N/A)
Other non-iatrogenic (n=9)	67 (59-73)	137 (52-258)	1 (11)	5 (2-19)	1 (11) / 100 / 12 (N/A)	7 (78) / 57 / 7 (5-15)	1 (11) / 0 / 10 (N/A)
AL: anastomotic leakage; EVT: endoscopic vacuum therapy; IQR: interquartile range; mm: millimeters; N/A: not applicable; yrs: years

Conclusion

This is the largest prospective EVT cohort to date. Results show high closure rates (77%) and few adverse events (7%).

Event

UEG Week Barcelona 2026

Topics

Oesophagus Histopathology Endoscopy Digestive Oncology

Submission format

Abstract

Session

Interventional endoscopy: What's new and cool!

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

The role of microbiota in MASLD: Basic science and clinical perspective

Herbert Tilg

INTERNATIONAL DELPHI CONSENSUS ON TRAINING IN DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC ULTRASOUND

Paolo Giorgio Arcidiacono

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

THE METABOLIC PRICE OF CURE: LONG-TERM ANTHROPOMETRIC, GLUCOSE AND LIPID SHIFTS FOLLOWING QUADRUPLE THERAPIES FOR HELICOBACTER PYLORI INFECTION

Pedro Narra Figueiredo

MAPS III guidelines: What’s next?

Mario Dinis-Ribeiro

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Surgery’s invisible enemy: Outsmarting infections before they start

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda 1

Affiliations

1 Queen Elizabeth University Hospital, Glasgow, United Kingdom

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Topics

Surgery Standards & Guidelines Oesophagus Colorectal

Session

From guidelines to clinical practice: Digestive guidelines unplugged – what’s new, what’s next?

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

The role of microbiota in MASLD: Basic science and clinical perspective

Herbert Tilg

INTERNATIONAL DELPHI CONSENSUS ON TRAINING IN DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC ULTRASOUND

Paolo Giorgio Arcidiacono

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

THE METABOLIC PRICE OF CURE: LONG-TERM ANTHROPOMETRIC, GLUCOSE AND LIPID SHIFTS FOLLOWING QUADRUPLE THERAPIES FOR HELICOBACTER PYLORI INFECTION

Pedro Narra Figueiredo

MAPS III guidelines: What’s next?

Mario Dinis-Ribeiro

UEG Poster

New

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

THE METABOLIC PRICE OF CURE: LONG-TERM ANTHROPOMETRIC, GLUCOSE AND LIPID SHIFTS FOLLOWING QUADRUPLE THERAPIES FOR HELICOBACTER PYLORI INFECTION

Elisa Gravito-Soares 1,2, Nuno Peres Almeida 1,2, Marta Gravito-Soares 1,2, Barbara Rocha 3,4, Maria Manuela Donato 1,2, Rafaela Trincão 1, Pedro Narra Figueiredo 2,1

Affiliations

1 Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal

2 Faculty of Medicine, University of Coimbra, Coimbra, Portugal

3 Center for Neuroscience and Celular Biology, University of Coimbra, Coimbra, Portugal

4 Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Helicobacter pylori (H. pylori) infection remains a major public health problem. Given the high resistance to antibiotics worldwide, quadruple regimens have emerged as first-line therapies for H. pylori infection, though their long-term consequences remain unclear.

Aims & Methods

Aim: This study aimed to evaluate major changes in the metabolic profile and body composition of patients submitted to H. pylori eradication using different quadruple therapies.
Methods: Patients were enrolled in a blind, randomized trial and assigned to one of five eradication regimens: A (Concomitant with metronidazole tid, 14 days); B (Concomitant with metronidazole bid, 14 days); C (Bismuth-containing Quadruple, 10 days); D (Sequential, 14 days); E (Hybrid, 14 days). Esomeprazole was the proton-pump inhibitor of choice. Efficacy, clinical safety, and metabolic changes including body composition by anthropometry and bioelectrical impedance analysis; lipid profile; glucose metabolism (glucose, insulin, glycohemoglobin, HOMA-IR); and systemic inflammation (ESR, CRP) were evaluated at 2- and 12-months post-treatment.

Results

A total of 233 patients completed the protocol (mean age 57.6±16.2 years; 52.8% males). Overall eradication and clinical adverse event rates were 97.9% and 53.6%, respectively. Following successful eradication, significant metabolic shifts were observed across all groups, including decreases in insulin and glycated hemoglobin (Z=4.04-5.12; p<0.03). Conversely, there was a significant increase in LDL-cholesterol, BMI, abdominal circumference, waist-to-hip ratio (WHR), total/visceral fat mass, and rates of obesity/visceral obesity (Z=4.33-13.05; p<0.03). Comparing the different treatment protocols, regimen B (Concomitant with metronidazole bid, 14 days) induced the most pronounced metabolic impact, significantly increasing WHR and total/visceral fat mass, compared to other therapies (Z=2.00-2.52; p<0.05). During follow-up, 37 patients (16.4%) experienced H. pylori recurrence, which was significantly associated with increased HDL-cholesterol and decreased fat-free mass (Z=2.26-6.95; p<0.05).

Conclusion

While quadruple therapies are highly effective for H. pylori eradication, they are associated with significant long-term metabolic and body composition shifts, most notably weight gain and increased visceral adiposity. The concomitant therapy with metronidazole bid was associated with the most pronounced worsening of anthropometric fat parameters. H. pylori recurrence tends to lead to a return to the metabolic profile observed prior to eradication. These findings highlight the potential need for metabolic surveillance and nutritional counseling following H. pylori eradication.

References

1. Zamani M , Ebrahimtabar F, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2018;47(7):868-876.
2. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017;66(1):6-30.
3. Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization Regions. Gastroenterology 2018;155(5):1372-1382.
4. Lopo I, Libânio D, Pita I, et al. Helicobacter pylori antibiotic resistance in Portugal: Systematic review and metaanalysis. Helicobacter 2018;23(4):e12493.
5. Bae SE, Choi KD, Choe J, et al. Effect of Helicobacter pylori Eradication on Metabolic Parameters and Body Composition including Skeletal Muscle Mass: A Matched Case-Control Study. Gut Liver. 2025;19(3):346-354.
6. Upala S, Sanguankeo A, Saleem SA, et al. Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(2):153-159.
7. Alavinejad P, Hajiani E, Parsi A, et al. Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study. BMC Gastroenterol. 2022;22(1):507.

Disclosure

None of the authors have anything to declare with regard to personal or financial interests in carrying out this work.

Conference

UEG Week Barcelona 2026

Topics

Oesophagus

Submission format

Abstract

Session

Uninvited guests: The persistent threat of Helicobacter and GI pathogens (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

The role of microbiota in MASLD: Basic science and clinical perspective

Herbert Tilg

INTERNATIONAL DELPHI CONSENSUS ON TRAINING IN DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC ULTRASOUND

Paolo Giorgio Arcidiacono

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

THE METABOLIC PRICE OF CURE: LONG-TERM ANTHROPOMETRIC, GLUCOSE AND LIPID SHIFTS FOLLOWING QUADRUPLE THERAPIES FOR HELICOBACTER PYLORI INFECTION

Pedro Narra Figueiredo

MAPS III guidelines: What’s next?

Mario Dinis-Ribeiro

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

MAPS III guidelines: What’s next?

Mario Dinis-Ribeiro 1

Affiliations

1 IPO Porto, Porto, Portugal

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Topics

Immunology Stomach & H. Pylori Oesophagus Digestive Oncology

Session

Management of upper GI: Precancerous conditions and early neoplasia

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

The role of microbiota in MASLD: Basic science and clinical perspective

Herbert Tilg

INTERNATIONAL DELPHI CONSENSUS ON TRAINING IN DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC ULTRASOUND

Paolo Giorgio Arcidiacono

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

THE METABOLIC PRICE OF CURE: LONG-TERM ANTHROPOMETRIC, GLUCOSE AND LIPID SHIFTS FOLLOWING QUADRUPLE THERAPIES FOR HELICOBACTER PYLORI INFECTION

Pedro Narra Figueiredo

MAPS III guidelines: What’s next?

Mario Dinis-Ribeiro